Unjustified increase in cost of care resulting from U.S. Food and drug administration approval of makena (17α-hydroxyprogesterone caproate)

Arnold W. Cohen, Joshua A. Copel, George A. MacOnes, M. Kathryn Menard, Laura Riley, George Saade

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

U.S. Food and Drug Administration (FDA) approval of 17α- hydroxyprogesterone caproate for the indication of decreasing the risk of preterm delivery in those high-risk patients who previously had spontaneous preterm birth has come at considerable cost to the health care system. Weekly injections provided by compounding pharmacies starting at 16-20 weeks of gestation and continuing until 36 weeks currently cost the health care system $200 to $300 per pregnancy. This cost is significantly less than the costs associated with delivering and caring for preterm children. Makena, by KV Pharmaceutical, the same 17α-hydroxyprogesterone caproate product, is priced at $1,500 per injection, or a projected cost of $30,000 per pregnancy. With approximately 132,000 pregnancies being eligible for treatment annually, this increase in cost of 75-150 times what previously had been paid far exceeds the benefits derived from the FDA-approved Makena when compared with previously available compounded versions of 17α-hydroxyprogesterone caproate. This increased health care cost is not justified at this time. The price barrier to access imposed by KV Pharmaceutical actually could result in an increase in preterm deliveries over current rates. Actions are needed by the FDA, national societies, and the manufacturer to ensure that all high-risk patients continue to get the needed therapy to reduce the number of preterm births.

Original languageEnglish (US)
Pages (from-to)1408-1410
Number of pages3
JournalObstetrics and Gynecology
Volume117
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

17-alpha-Hydroxyprogesterone
Drug Approval
Costs and Cost Analysis
Food
Pregnancy
Premature Birth
United States Food and Drug Administration
Delivery of Health Care
Injections
Pharmacies
Pharmaceutical Preparations
Health Care Costs
17-alpha-hydroxy-progesterone caproate
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Unjustified increase in cost of care resulting from U.S. Food and drug administration approval of makena (17α-hydroxyprogesterone caproate). / Cohen, Arnold W.; Copel, Joshua A.; MacOnes, George A.; Menard, M. Kathryn; Riley, Laura; Saade, George.

In: Obstetrics and Gynecology, Vol. 117, No. 6, 06.2011, p. 1408-1410.

Research output: Contribution to journalArticle

Cohen, Arnold W. ; Copel, Joshua A. ; MacOnes, George A. ; Menard, M. Kathryn ; Riley, Laura ; Saade, George. / Unjustified increase in cost of care resulting from U.S. Food and drug administration approval of makena (17α-hydroxyprogesterone caproate). In: Obstetrics and Gynecology. 2011 ; Vol. 117, No. 6. pp. 1408-1410.
@article{2b7c9cd1eb3746ebb7680bf72afe47c4,
title = "Unjustified increase in cost of care resulting from U.S. Food and drug administration approval of makena (17α-hydroxyprogesterone caproate)",
abstract = "U.S. Food and Drug Administration (FDA) approval of 17α- hydroxyprogesterone caproate for the indication of decreasing the risk of preterm delivery in those high-risk patients who previously had spontaneous preterm birth has come at considerable cost to the health care system. Weekly injections provided by compounding pharmacies starting at 16-20 weeks of gestation and continuing until 36 weeks currently cost the health care system $200 to $300 per pregnancy. This cost is significantly less than the costs associated with delivering and caring for preterm children. Makena, by KV Pharmaceutical, the same 17α-hydroxyprogesterone caproate product, is priced at $1,500 per injection, or a projected cost of $30,000 per pregnancy. With approximately 132,000 pregnancies being eligible for treatment annually, this increase in cost of 75-150 times what previously had been paid far exceeds the benefits derived from the FDA-approved Makena when compared with previously available compounded versions of 17α-hydroxyprogesterone caproate. This increased health care cost is not justified at this time. The price barrier to access imposed by KV Pharmaceutical actually could result in an increase in preterm deliveries over current rates. Actions are needed by the FDA, national societies, and the manufacturer to ensure that all high-risk patients continue to get the needed therapy to reduce the number of preterm births.",
author = "Cohen, {Arnold W.} and Copel, {Joshua A.} and MacOnes, {George A.} and Menard, {M. Kathryn} and Laura Riley and George Saade",
year = "2011",
month = "6",
doi = "10.1097/AOG.0b013e31821c2d75",
language = "English (US)",
volume = "117",
pages = "1408--1410",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Unjustified increase in cost of care resulting from U.S. Food and drug administration approval of makena (17α-hydroxyprogesterone caproate)

AU - Cohen, Arnold W.

AU - Copel, Joshua A.

AU - MacOnes, George A.

AU - Menard, M. Kathryn

AU - Riley, Laura

AU - Saade, George

PY - 2011/6

Y1 - 2011/6

N2 - U.S. Food and Drug Administration (FDA) approval of 17α- hydroxyprogesterone caproate for the indication of decreasing the risk of preterm delivery in those high-risk patients who previously had spontaneous preterm birth has come at considerable cost to the health care system. Weekly injections provided by compounding pharmacies starting at 16-20 weeks of gestation and continuing until 36 weeks currently cost the health care system $200 to $300 per pregnancy. This cost is significantly less than the costs associated with delivering and caring for preterm children. Makena, by KV Pharmaceutical, the same 17α-hydroxyprogesterone caproate product, is priced at $1,500 per injection, or a projected cost of $30,000 per pregnancy. With approximately 132,000 pregnancies being eligible for treatment annually, this increase in cost of 75-150 times what previously had been paid far exceeds the benefits derived from the FDA-approved Makena when compared with previously available compounded versions of 17α-hydroxyprogesterone caproate. This increased health care cost is not justified at this time. The price barrier to access imposed by KV Pharmaceutical actually could result in an increase in preterm deliveries over current rates. Actions are needed by the FDA, national societies, and the manufacturer to ensure that all high-risk patients continue to get the needed therapy to reduce the number of preterm births.

AB - U.S. Food and Drug Administration (FDA) approval of 17α- hydroxyprogesterone caproate for the indication of decreasing the risk of preterm delivery in those high-risk patients who previously had spontaneous preterm birth has come at considerable cost to the health care system. Weekly injections provided by compounding pharmacies starting at 16-20 weeks of gestation and continuing until 36 weeks currently cost the health care system $200 to $300 per pregnancy. This cost is significantly less than the costs associated with delivering and caring for preterm children. Makena, by KV Pharmaceutical, the same 17α-hydroxyprogesterone caproate product, is priced at $1,500 per injection, or a projected cost of $30,000 per pregnancy. With approximately 132,000 pregnancies being eligible for treatment annually, this increase in cost of 75-150 times what previously had been paid far exceeds the benefits derived from the FDA-approved Makena when compared with previously available compounded versions of 17α-hydroxyprogesterone caproate. This increased health care cost is not justified at this time. The price barrier to access imposed by KV Pharmaceutical actually could result in an increase in preterm deliveries over current rates. Actions are needed by the FDA, national societies, and the manufacturer to ensure that all high-risk patients continue to get the needed therapy to reduce the number of preterm births.

UR - http://www.scopus.com/inward/record.url?scp=79958130486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958130486&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e31821c2d75

DO - 10.1097/AOG.0b013e31821c2d75

M3 - Article

VL - 117

SP - 1408

EP - 1410

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 6

ER -